Compare Moderna, Inc. (MRNA) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs UiPath Inc — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while UiPath Inc trades at $12.03 (market cap $6.30B). The key difference: Moderna, Inc. is far larger — about 3.7× UiPath Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | PATH | |
|---|---|---|
Market Cap | $23.60B | $6.30B |
Sector | Health | Technology |
52-Week High | $81.80 | $19.29 |
52-Week Low | $22.36 | $9.38 |
Enterprise Value | $19.70B | $5.08B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
